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Renin–angiotensin system (RAS) blockers are
extensively used worldwide to treat many cardio-
vascular disorders, where they are effective in
reducing both mortality and morbidity. These
drugs are known to induce an increased expression
of angiotensin-converting enzyme 2 (ACE2). ACE2
acts as receptor for the novel SARS coronavirus-2
(SARS-CoV-2) which raising the important issue of
possible detrimental effects that RAS blockers
could exert on the natural history and pathogen-
esis of the coronavirus disease-19 (COVID-19) and
associated excessive inflammation, myocarditis
and cardiac arrhythmias. We review the current
knowledge on the interaction between SARS-CoV-2
infection and RAS blockers and suggest a scientific
rationale for continuing RAS blockers therapy in
patients with COVID-19 infection.
Keywords: cardiovascular system, COVID-19, SARS
coronavirus (CoV)-2, pandemic, angiotensin-con-
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Introduction
The past 2 decades have witnessed three lethal
zoonotic diseases of humans caused by novel
coronaviruses: the severe acute respiratory syn-
drome (SARS) in 2002, the Middle East respiratory
syndrome (MERS) in April 2012, and currently,
coronavirus disease-19 (COVID-19) caused by
SARS-CoV, MERS-CoV and SARS-CoV-2, respec-
tively. All three coronaviruses are listed in the WHO
Blueprint list for priority pathogens [1]. Coron-
aviruses are members of the Coronaviridae family,
a heterogeneous family of RNA viruses that cause
respiratory tract infections in humans. HCoV-
229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1
cause mild infections whilst MERS-CoV, like SARS-
CoV and SARS-CoV-2, can cause a spectrum of
clinical manifestations from mild to severe disease
and death [2].
The ongoing global pandemic of SARS coronavirus-
2 (SARS-CoV-2) has affected almost 3 millions of
people in all continents [3]. The high death rate has
been attributed to comorbidities of diabetes, hyper-
tension, coronary artery disease amongst others
[4]. Renin–angiotensin system (RAS) blockers are
extensively used worldwide to treat many cardio-
vascular disorders, where they are effective in
reducing both mortality and morbidity. These
drugs are known to induce an increased expression
of angiotensin-converting enzyme 2 (ACE2).
SARS-CoV-2 binds to human cells via angiotensin-
converting enzyme 2 (ACE2), which is expressed on
epithelial cells of the lung, kidney, intestinal tract
and blood vessels [5]. ACE2 expression is increased†These authors contributed equally to the study.
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in patients with diabetes. Hypertension, treated
with ACE inhibitors and ARBs, results in an
upregulation of ACE2, which theoretically could
enhance SARS-CoV-2 infection [6]. Therefore, since
SARS-CoV-2 strongly interacts with ACE2,
patients undergoing chronic RAS blocker treat-
ment may be more prone to SARS-CoV2 infection
or develop worse forms of COVID-19. In this review,
we will discuss some aspects of the viral–cell
interaction, pathophysiology and the ACEIs/ARBs
action mechanism. Lastly, we suggest a scientific
rationale for continuing RAS blockers therapy in
patients with COVID-19 infection, thus providing
both those clinicians working in the emergency
setting and facing with acute cardiovascular dis-
eases, and those following outpatients receiving
ACEI/ARBs during the COVID-19 pandemic, a
basis for their therapeutic decision-making.
Renin–angiotensin–aldosterone system blockade in cardiovascular
diseases
As widely described in literature [7], the complex
renin–angiotensin system (RAS) plays a crucial role
in the pathophysiology of several morbidities, such
as hypertension, diabetes mellitus, myocarditis [8],
heart failure and myocardial infarction, where the
use of RAS blockers is essential for management.
ACE inhibitors (ACEIs) and/or angiotensin II
receptor blockers (ARBs) delay or prevent the onset
of heart failure in asymptomatic patients with left
ventricular systolic dysfunction and, importantly,
reduce both mortality and morbidity of patients
with heart failure and reduced ejection fraction. In
these patients, ACEIs/ARBs are titrated to the
upper tolerated dose to achieve adequate RAS
inhibition [9,10]. The most recent ESC guidelines
recommend employing ACEIs/ARBs as antihyper-
tensive treatment to prevent cardiovascular events
and heart failure in diabetic patients, particularly
in those with cardiovascular complications [11].
Also, ESC guidelines on hypertension give IA
recommendation for employment of ACEIs and
ARBs as antihypertensive drugs with demon-
strated efficacy in blood pressure and cardiovas-
cular events reduction [12]. Further, hemodynamic
changes after an acute myocardial infarction cause
a strong activation of both the circulating and the
local RAS [13]. This adaptive response [14] could be
dangerous and contributes to the development of
cardiac structural and electrophysiological remod-
elling [15,16]. The effects of RAS inhibition are
beneficial [17] in all patients after a myocardial
infarction and are more prominent in more severe
patients [18]. Further, in one systematic overview
including 100,000 patients, it was observed that
the most significant short-term survival benefit
occurs if treatment with ACEIs is started within the
first 7 days (40% in days 0 to 1, 45% in days 2 to 7,
15% subsequently) [19]. In line with this, guideli-
nes provide class IA/IB recommendation to com-
mence ACEIs/ARBs treatment within the first 24h
after the acute event in all ST-segment elevation
myocardial infarction (STEMI) patients with left
ventricular systolic dysfunction, heart failure,
anterior STEMI or diabetes [18,20]. Treatment with
ACEIs/ARBs is also recommended (class IA/IB) in
non-ST-segment elevation myocardial infarction
(NSTEMI) patients with left ventricular systolic
dysfunction, heart failure, hypertension or dia-
betes mellitus, in order to reduce mortality and risk
of recurrent ischaemic event or hospitalization for
heart failure [21,22].
Angiotensin-Converting enzyme 2 (ACE2)
In the context of SARS-CoV-2 infection, it is impor-
tant to note that ACEIs/ARBs increase the local
expression and activity of angiotensin-converting
enzyme 2 (ACE2) [23], a zinc metalloprotease that
exists both as amembrane-associated formandas a
secreted form.ACE2 isubiquitously expressed,with
the highest levels of transcripts being found in the
lung, the heart and the gastrointestinal and urinary
systems. ACE2 is mostly expressed in lung alveolar
type II (AT2) cells, myocardial cells, vascular
endothelia, buccal epithelial cells, T and B lympho-
cytes, on the proximal tubule epithelial cells in the
kidney, and in testes [24,25]. All cardiac cell com-
ponents (i.e. endothelial cells, smooth muscle cells,
cardiac myocytes, fibroblasts and macrophages)
express ACE2, although the highest levels were
observed in vascular cells, especially pericytes
[26,27]. Upregulation of ACE2 expression has been
documented in patients affected by myocardial
infarction or heart failure. However, in animal
models of ageing, pressure overload and chronic
ischaemia, ACE2 downregulation has been associ-
ated with cardiac hypertrophy, adverse remodelling
and fibrosis [28-30]. Conversely, ACE2 expression
is reduced in hypertension, advanced diabetes
mellitus and atherosclerotic plaques and, experi-
mentally, by both angiotensin II (Ang II) and
endothelin [28-31]. Importantly, it has been esti-
mated that heritability accounts for 67% of the
variability in ACE2 circulating levels. Moreover,
ACE2 genetic variants have been associated with
both essential hypertension and coronary heart
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disease (CHD), whilst they act as disease modifiers
of both hypertrophic and dilated cardiomyopathies
[31]. Concerning development, it was shown that
ACE2 protein levels and activity are high during
gestation and decline postnatally [32].
ACE2 acts as a negative regulator of RAS, by
degrading AngII to the heptapeptide angiotensin 1-
7 (Ang1-7) [33], that exerts its biological activity
via the Mas receptor, modulating the release of
nitric oxide (NO), antagonizing the intracellular
effect of AngII stimulation (thus tempering the
production of reactive oxygen species), at least in
part by activating intracellular phosphatases [34].
As a result, Ang1-7 exerts many positive effects on
the cardiovascular system (e.g. increased endothe-
lial function, reduced fibrosis, anti-proliferative
effects on smooth muscle cells, anti-cardiac hyper-
trophy), as well as on other organs, such as the
lungs, where it exerts anti-fibrotic, anti-inflamma-
tory and anti-apoptotic effects [35-37]. Moreover,
ACE2 cleaves other peptides and plays a central
role in inactivating des-arginine(9)-bradykinin
(des-Arg(9)-BK), a potent metabolite of the kinin–
kallikrein system that increases vascular perme-
ability, thus promoting angioedema, acting on B1
type receptors, which are, in turn, upregulated by
inflammatory cytokines [38,39]. According to some
authors, the leakage of plasma in the subendothe-
lial compartment in conjunction with the inflam-
matory response triggered by the host–virus
interaction may have a central pathogenetic role
in the endotheliitis and disseminated intravascu-
lar coagulation that have been documented to
occur in COVID-19 patients [39-41]. ACE2 plays
an important role in heart failure, in diabetic
microvascular or macrovascular disease [42] and
in inflammatory lung disease [43], and ACEIs/
ARBs-mediated increase in ACE2 exerts a protec-
tive role in many conditions such as atherosclero-
sis, myocardial infarction, myocardial dysfunction,
heart failure, diabetes mellitus and acute lung
injury (ALI).
SARS-COV-2 Infection and host injury
Although the details have not been completely
elucidated yet, SARS-CoV-2 was originated either
as a result of natural selection that took place in a
host before zoonotic transfer or by natural selec-
tion in humans after the zoonotic transfer had
occurred [44,45]. Importantly, during the selection
process, the virus acquires a furin cleavage site
and three predicted O-linked glycans around the
site that are very likely associated with the acqui-
sition of a highly pathogenic phenotype [44].
Virus – entry and spread
Coronaviruses’ (SARS-CoV, SARS-CoV-2) Spike (S)
protein, binds with high affinity to human ACE2
[45] (Figure 1). Before SARS-CoV-2 and SARS-CoV
cell entry, their S protein is subjected to a priming
process via serine protease TMPRSS2 in order
permit the attachment of viral particles to ACE2
and thus on cell surface [46]. This entry mecha-
nism is confirmed by the fact that TMPRSS2
inhibition or TMPRSS2-KO mice show both
decreased, though not abolished, S protein prim-
ing, and reduced viral entry, spread, and inflam-
matory chemokine and cytokine release [46,47].
SARS-CoV-2 is then internalized mainly by endo-
cytosis. In this process, phosphatidylinositol 3-
phosphate 5-kinase (PIKfyve), two pore channel
subtype 2 (TPC2) and cathepsin L are critical for
virus entry [48]. SARS-CoV binding also induces
the release/shedding of catalytically active ACE2
ectodomains via ADAM-17⁄TACE activity [49-52].
In line, inhibition of ADAM17/TACE blocks ACE2
shedding and limits viral entry in both in vitro and
in vivo [53]. Intriguingly, recent data show that
soluble ACE2 (sACE2) could inhibit S-mediated
infection in vitro. Although sACE2 was not able to
completely abrogate viral entry, ACE2 shedding
may help in contrasting viral diffusion to different
organs [54]. Conversely, it has been demonstrated
that ACE2 downregulation following infection has a
detrimental effect in the pathogenesis of ALI [55],
although this effect could be limited, judging by the
amount of ACE2 expressed by the AT2 cells of the
lungs, or the ratio between ACE2 and circulating
sACE2 [24,56,57]. Altogether, these results sug-
gest that ACE2 might not be the only receptor for
SARS-CoV-2. In fact, recent structural and predic-
tive studies proposed other receptor-mediated
mechanisms for SARS-CoV-2 cell entry, indicating
three other aminopeptidases, alanyl aminopepti-
dase (ANPEP), glutamyl aminopeptidase (ENPEP)
and dipeptidyl peptidase 4 (DPP4), as the most
probable additional receptors [58,59].
Virus-direct negative effects
It is known that the virus survival strategy is to
elude and suppress host innate immune defences
through gene deactivation or inhibition [57,60,61].
In line, Huang et al. demonstrated that SARS-CoV
nonstructural protein (nsp1) binding to ribosomes
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Figure 1 The figure summarizes SARS-CoV, and presumably SARS-CoV-2, confirmed and hypothesized mechanism of
viral binding, internalization and shedding via ACE2 interaction, and the successive downregulative effect on ACE2 and the
resulting pathogenic effect on lung and cardiac tissues. Abbreviations: angiotensin-converting enzyme 2 (ACE2);
angiotensin (Ang); angiotensin 1-7 (Ang 1-7); transmembrane protease, serine 2 (TMPRSS2); ADAM metallopeptidase
domain 17 (ADAM-17); tumour necrosis factor-a converting enzyme (TACE); SMAD family member2, 7 (SMAD2, SMAD7);
nonstructural protein 1 (nsp-1); SARS-CoV nucleocapsid (N) protein (N protein); interleukin-2, 7, 10 (IL-2, 7,10); granulocyte
colony-stimulating factor (G-CSF); transforming growth factor-a (TNF-a); monocyte chemoattractant protein 1 (MCP-1).
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inhibits host gene translation [62]. More precisely,
a marked downregulation of ACE2 mRNA and
protein expression was associated with the pres-
ence of SARS-CoV and (HCoV)-NL63 (another
human coronavirus, causing mild to severe respi-
ratory tract infections, excluding SARS) in target
tissues [63]. However, whilst SARS-CoV induced
ACE2 shedding from the cell surface, (HCoV)-NL63
did not, suggesting that ACE2 shedding is directly
related with prognostic severity [30,52,53]. Addi-
tionally, a viral titre- and infection time-related
SARS-CoV effect on ACE2 mRNA has been shown,
where lower viral titre is associated with upregula-
tion instead, higher dosage and time after infection
are correlated to reduced ACE2 expression [64].
Last, since interleukin (IL)-2, IL-7, IL-10, G-CSF,
IP-1 MCP-1 MIP-1a and TNF-a are highly increased
in patients with severe SARS-CoV infection, with
respect to patients with mild symptoms, it was
hypothesized that ACE2 suppression could result
from a direct cell driven effect, rather than virus
mediated. In line, in vitro data could support a
suppressive role for IL7 and IL2 on Ace2 expression
[64].
Acute Lung Injury – ALI
Part of the conundrum related to the role of ACE2
in SARS-CoV-2 infection (designated coronavirus
disease-19 or COVID-19) is related to the role
exerted by this enzyme in ALI. Indeed, ALI that can
be caused by a number of aetiological agents (e.g.
influenza and coronaviruses, bacterial pneumonia,
sepsis [65], cigarette smoking [66], particulate
matter [67] and aspiration pneumonia [68]) has
been associated with the activation of the local RAS
[69]. Ang II, by acting on AngII type 1 receptor
(AT1R), activates several signal transduction path-
ways, including mitogen-activated protein kinase
(MAPK) and Janus-activated kinase (JAK)/ signal
transducer and activator of transcription 3
(STAT3), phosphatidylinositol 3 kinase (PI3K), pro-
moting vascular permeability, vasoconstriction,
myofibroblast, smooth muscle cell and macro-
phage activation, fibrosis, and the expression of
inflammatory cytokines [65,70,71]. The latter effect
has been mainly attributed to the ability of AngII to
activate the transcription factor NFjB via AT1R
[72]. AngII may also bind to other receptors, the
most studied of which is type 2 receptor (AT2R).
However, the net effect of AT2R stimulation is less
clear since both pro- and anti-inflammatory effects
have been described [57]. To corroborate the cru-
cial role exerted by pulmonary RAS on ALI, it was
shown that AngII levels are increased in animal
models of ALI [73]. Importantly, recent reports on
SARS-CoV-2-infected patients showed a significant
increase in Ang II plasma level that was inversely
correlated with viral load [74]. In line, survivors of
acute respiratory distress syndrome (ARDS) have
been associated with lower plasmatic ACE levels, in
a preliminary report [75]. Moreover, by evaluating
the levels of angiotensinogen metabolites, it was
shown that ARDS outcome was associated with
higher Ang1-9/Ang1-10 and Ang1-7/Ang1-10
ratios, suggesting higher activity of both ACE and
ACE2 in survivors [76]. Conversely, AT1R blockage
resulted in the protection of animal models of lung
injury [77]. Further, an accumulating body of
literature is showing the protective role exerted by
ACE2 on ALI. Indeed, ACE2 knockout animals
develop more severe forms of ALI in response to a
series of injurious stimuli [67,73,75]. Conversely,
the results of clinical trials that experimented the
administration of soluble ACE2 to treat patients
suffering from ARDS, although in early phase and
not designed to test efficacy, did not show very
promising results [78]. Moreover, as anticipated,
ACE2 downregulation causes also accumulation of
des-Arg(9)-BK, which interacts with type B1 bra-
dykinin receptor, possibly leading to the observed
development of angioedema, and coagulation cas-
cade triggering [39]. Last, the protective effect of
ACE2 may be also postulated considering both that
ACE2 levels decrease with age and that, although
children are vulnerable to the infection, these
patients are usually less severe [79].
Myocardial injury
The relevance of myocardial involvement in SARS-
CoV-2 infection is related to the high frequency of
patients showing evidence of acute cardiac injury,
especially amongst those that necessitated ICU
care [80]. This finding is similar to that observed in
patients that succumbed to the SARS crisis in
Toronto, where the duration of disease was almost
10 times shorter in patients that showed cardiac
involvement vs. those that had no evidence of
cardiac infection [30]. In line, a recent report
suggests that the SARS-CoV-2 infection can be
complicated by acute fulminant myocarditis [81].
In this scenario, left ventricular function com-
pletely recovered early after immunomodulation
therapy [82] suggesting that organ damage in these
patients is more the consequence of a ’cytokine
storm’, than of an uncontrolled viral replication
[80,82,83]. To complete the picture, the presence of
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viral particles infecting myocardial interstitial cells,
but neither endothelial cells nor myocytes, was
recently described to occur in one patient that died
of COVID-19, with a clinical scenario characterized
by respiratory distress, hypotension and cardio-
genic shock [84].
Consistently, SARS-CoV-2-infected patients were
characterized by high amounts of plasmatic IL1b,
IFNc, IP10 and MCP1 levels. Additionally, more
severe patients had higher concentrations of G-
CSF, IP10, MCP1, MIP1A and TNF-a, strongly
supporting the relevance of cytokines in dictating
prognosis [80]. This observation has stimulated
early trials experimenting IL6 axis inhibition in
COVID-19 patients [82]. Cytokine-mediated sys-
temic response to infections can be associated with
transient cardiac dilatation and dysfunction [85].
However, local viral replication could depress car-
diac function too. Indeed, SARS-CoV can activate
the NLRP3 inflammasome [86], thus promoting the
release of IL1b and possibly IL18, a mediator
known to cause systolic impairment [87]. Notably,
extrapulmonary, multiorgan SARS-CoV dissemi-
nation at the time of death was described in
patients who died of SARS during the Toronto
outbreak [88] and SARS-CoV viral RNA was
detected in 35-40% of cardiac autopsy samples
[30,88]. Histology studies conducted on these
hearts showed cardiomyocyte hypertrophy, fibrosis
and an inflammatory infiltrate, mainly constituted
by CD68+ macrophages [30]. However, necropsy of
39-year-old woman who died from SARS-CoV, with
severe left ventricular dysfunction at echocardio-
graphic evaluation, has shown slight left ventricu-
lar enlargement without evidence of interstitial
lymphocytic infiltrate or cardiomyocyte necrosis
[89]. Importantly, in one postmortem cardiac spec-
imen of a 50-year-old patient who died from SARS-
CoV-2 infection, only limited interstitial mononu-
clear cell infiltrates without significant injury were
described [90]. Similar findings, characterized by
CD68+ macrophage infiltrates showing evidence of
a cytopathic effect, were recently reported in a case
report of a 69-year-old patient that died from
COVID-19 [84]. The paucity of lymphocyte infil-
trate observed in these reports may be explained by
the severe lymphopenia that accompanies COVID-
19 [80].
The mechanism of negative effect on myocardial
tissue of SARS-CoV infection was hypothesized to
be related to both ACE2 downregulation and
cytokine storm [63,82]. As outlined above, ACE2
expression may be reduced both by the binding of
SARS-CoV to ACE2, leading to the endocytosis of
the latter [91], and as a result of the activation of
ADAM-17/TACE by SARS spike protein, known to
cleave, internalize and promote ACE2 shedding in
endothelial cells [49]. Downregulation of ACE2
results in an unbalance between the detrimental
action of AngII and the cardioprotective effects of
Ang1-7. Further, more chronic negative conse-
quences on the cardiovascular system might be
related to ACE2 downregulation via des-Arg(9)-BK
accumulation and its consequential increase in
vascular permeability, inflammation that leads to
an increased atherosclerotic plaques formation
[92]. Further, ADAM-17⁄TACE activation, induced
by the spike protein, promotes TNF-a release, thus
increasing macrophage mobilization and activation
[49,52]. Moreover, SARS-CoV nucleocapsid (N)
protein potentiates TGF-b-mediated fibrosis [93].
ACEIs/ARBs treatment during the COVID-19 pandemic
On the basis of the increase of ACE2, associated
with ACEIs/ARBs treatment, it has been specu-
lated that these drugs might rise the chances of
severe COVID-19 [94]. According to the last report
(29th April 2020) from the Italian Istituto Superiore
di Sanita, 25.452 patients positive to SARS-CoV-2
died. The observed mortality was higher amongst
males in all age groups and in patients with
comorbidities. In 9.23% of the total sample, data
regarding comorbidities were available; 81.7% of
the deceased patients had 2 or more comorbidities,
such as arterial hypertension (69.2%), diabetes
mellitus (31.8%) and CHD (28.2%). Similar data
regarding comorbidities and gender differences in
mortality were observed during China COVID-19
emergency [95]. Prior to hospitalization, 24% of
COVID-19-positive deceased Italian patients were
on treatment with ACEIs and 16% were receiving
ARBs.
The gender difference in mortality could be related
to the smoking prevalence and sex-based immuno-
logical differences. Moreover, a recent study sug-
gests that ACE2 expression seems to be higher in
women than men and to decrease with age
[64,96,97]. The more severe prognosis of patients
of older age may also been related to distinct
mechanisms, such as the age-associated decline
in the molecular machinery involved in removing
cytosolic DNA [98]. Also, patients with hyperten-
sion or diabetes show high rate of ACE2 genetic
polymorphism that could influence ACE2 or Ang1–
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7 levels in the human body [64,99-101]. Therefore,
a negative correlation between ACE2 expression
and mortality has been suggested [64].
Should indications for ACEIs/ARBs treatment change for patients
with COVID-19?
An enormous body of literature shows that ACEIs/
ARBs should be given as early as possible to all
patients with acute myocardial infarction, in
asymptomatic patients with left ventricular systolic
dysfunction, in patients with heart failure and
reduced ejection fraction, as well in hypertensive
or diabetic patients, for their important benefits for
patient survival. Conversely, an abrupt discontinu-
ation of ACEIs, in survivors of myocardial infarction
on long-term treatment [102,103] or in patients with
heart failure [104], can be potentially harmful.
Further, at the time of this pandemic COVID-19,
there are no experimental or strong clinical data to
contraindicate this therapy whilst, on the contrary,
some are supporting the opposite [105,106].
Calcium channel blockers were suggested as alter-
native treatment for ACEIs and ARBs [107]. How-
ever, since the development and progression of the
remodelling process after an myocardial infarction,
in setting of heart failure, hypertension or diabetes
mellitus depends on neurohormonal activation,
only medications, which block the effect of neuro-
hormones [108], have demonstrated to reduce
morbidity and mortality of patients. For calcium
channel blockers, in spite of their beneficial hemo-
dynamic activities, there is no evidence supporting
their ability to exert favourable effect early after an
acute myocardial infarction on preventing heart
failure in diabetics with hypertension and on
general mortality reduction [18,109,110]. Lastly,
calcium channel blockers have a strong interaction
with antiviral drugs (lopinavir/ritonavir) used to
treat COVID-19 patients.
In a recent retrospective observational study from
Wuhan, including 188 hypertensive subjects
affected by COVID-19, treatment ACEIs/ARBs
was associated with lower all-cause mortality
[105]. Furthermore, a large population-based
case–control study performed in Lombardy during
the ongoing COVID-19 epidemic spread on more
than 6000 COVID-19 patients did not show evi-
dence that the use of either ARBs, or ACEIs, affects
the risk of COVID-19 infection [111]. Italian Reg-
ulatory Agency (AIFA) recommended on 17 March
2020 do not to modify the therapy in progress with
anti-hypertensives (whatever the therapeutic class)
in well-controlled hypertensive patients, as they
expose frail patients to potential new side effects or
an increase in risk of adverse cardiovascular
events does not appear justified. For the same
reasons, compared to the hypothesis of using ACE
inhibitors and sartans also in healthy people for
prophylactic purposes, remembered that these
drugs should be used exclusively for the treatment
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Conclusions
As depicted in Figure 1, the interaction between
SARS-CoV-2 and the host cell promotes a series of
complex alterations leading to both the downregu-
lation of ACE2 expression and the increased pro-
duction and release of inflammatory cytokines. The
net loss of the ACE2/Ang1-7 anti-inflammatory
properties, along with a dysregulated vascular
permeability ACE2/des-Arg(9)-BK mediated and
the pro-inflammatory properties of secreted cytoki-
nes, may be therefore responsible for a large part of
the detrimental effects caused by COVID-19. Tak-
ing into account, the evidences presented in this
review, and at present, there are no data demon-
strating adverse outcomes amongst COVID-19
patients in therapy with ACE/ARBs; on the con-
trary, it seems that the treatment discontinuation
could have plausible negative effects. Thus,
according with the recommendations of the main
cardiovascular international [113,114] and Italian
scientific societies [115,116], patients chronically
taking ACEI/ARBs who contract COVID-19 infec-
tion should not discontinue the treatment, neither
temporarily (Figure 2). Further researches are
needed to indagate some uncleared and controver-
sial aspects of the pandemics.
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